Pilot Study of Magnesium Infusions in Pediatric Asthma
|ClinicalTrials.gov Identifier: NCT01522040|
Recruitment Status : Withdrawn
First Posted : January 31, 2012
Last Update Posted : March 30, 2017
|Condition or disease||Intervention/treatment||Phase|
|Asthma||Drug: Magnesium Sulfate Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||A Pilot Study of Magnesium Infusions (Drips) for Moderate-to-Severe Pediatric Asthma Exacerbations|
|Study Start Date :||January 2012|
|Primary Completion Date :||October 2013|
|Study Completion Date :||October 2013|
Active Comparator: Magnesium
Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
Drug: Magnesium Sulfate
Continuous magnesium drip, titrated to effect until patient's symptoms improve
Placebo Comparator: Control
Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
Simple saline drip, without active drug
- Time to discharge [ Time Frame: Duration of hospital stay, typically 3-5 days ]The primary outcome for this study is elapsed time from emergency department (ED) presentation to readiness for PICU discharge.
- Beta receptor haplotype [ Time Frame: Once on enrollment ]The subject's genetic haplotype for beta adrenergic receptor. It will be determined by blood test during their admission in the hospital and enrollment on the study protocol.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01522040
|United States, Kentucky|
|Kosair Children's Hospital|
|Louisville, Kentucky, United States, 40204|
|Principal Investigator:||Keith Cross, MD||University of Louisville|